CNS Pharmaceuticals Stock Price, News & Analysis

CNS Pharmaceuticals (NASDAQ:CNSP) reported its Q1 2025 financial results and provided updates on its lead program TPI 287. The company reported a net loss of $4.3 million, up from $3.5 million in Q1 2024, with R&D expenses increasing to $3.2 million. CNS ended Q1 with $13.1 million in cash and subsequently raised an additional $5 million through a public offering in May 2025, extending their cash runway into H2 2026. The company's lead drug candidate, TPI 287, an abeotaxane for treating glioblastoma multiforme (GBM), showed promising Phase 1 results with 3 Complete Responses and 9 Partial Responses out of 23 evaluable patients when combined with bevacizumab. CNS plans to commence a Phase 2 study around year-end 2025 and will engage with FDA for study design feedback. The company successfully transferred Orphan Drug Designations from Cortice Biosciences for TPI 287 in treating gliomas, pediatric neuroblastoma, and progressive supranuclear palsy.

CNS Pharmaceuticals (NASDAQ:CNSP) has announced the pricing of a $5 million public offering with a single healthcare-focused institutional investor. The offering includes 3,952,570 shares of common stock priced at $1.265 per share. Additionally, the company will issue Series F Warrants to purchase up to 3,952,570 shares with an exercise price of $1.14 per share, exercisable immediately and expiring in five years.

The offering is expected to close around May 14, 2025. A.G.P./Alliance Global Partners is serving as the sole placement agent. The company plans to use the net proceeds for working capital and general corporate purposes. The offering is made pursuant to an effective registration statement on Form S-1.

CNS Pharmaceuticals (NASDAQ:CNSP) has successfully acquired Orphan Drug Designation for TPI 287, a novel abeotaxane drug, from Cortice Biosciences. The FDA previously granted these designations for treating gliomas, pediatric neuroblastoma, and progressive supranuclear palsy.

TPI 287 works similarly to other taxanes by stabilizing microtubules and inhibiting cell division. Unlike most taxanes, clinical data suggests it can cross the blood-brain barrier. In a Phase 1 trial combining TPI 287 with bevacizumab for glioblastoma treatment, 3 Complete Responses and 9 Partial Responses were observed among 23 evaluable patients.

The company plans to begin Phase 2 study enrollment by year-end 2025. The Orphan Drug Designation provides benefits including tax credits, FDA fee exemptions, and potential 7-year market exclusivity post-approval.

CNS Pharmaceuticals (NASDAQ:CNSP) reported its full year 2024 financial results, highlighting a net loss reduction to $14.9 million from $18.9 million in 2023. The company's primary Berubicin trial for glioblastoma multiforme (GBM) did not meet its primary endpoint of statistical superiority in overall survival compared to Lomustine.

Research and development expenses decreased to $9.3 million from $14.1 million, while general and administrative expenses increased to $5.6 million from $4.8 million. The company holds approximately $6.5 million in cash and raised an additional $9.9 million through stock sales, providing operational funding into Q1 2026.

Moving forward, CNSP is pivoting to develop TPI 287, a novel abeotaxane licensed from Cortice Biosciences in July 2024. TPI 287 has shown promising clinical efficacy in GBM treatments and has received Orphan Drug Designation, with plans to engage FDA for potential registration study design in 2025.

CNS Pharmaceuticals (NASDAQ:CNSP) has announced the primary analysis of its clinical trial for Berubicin, an anthracycline treatment for recurrent Glioblastoma Multiforme (GBM). The study compared Berubicin to Lomustine, a standard GBM treatment.

Key findings show that while Berubicin did not demonstrate statistically significant superiority in overall survival (the primary endpoint), it showed comparable clinical outcomes to Lomustine across multiple endpoints. Notably, Berubicin displayed no cardiotoxicity, a common limitation with other anthracyclines, and maintained a favorable safety profile.

The drug is significant as the first anthracycline proven to extensively cross the blood-brain barrier. The company is continuing analysis of outcomes, including advanced imaging review and clinical endpoints. Additionally, CNS Pharmaceuticals is developing TPI 287, a novel taxane with published clinical efficacy data in GBM treatment.

CNS Pharmaceuticals (NASDAQ:CNSP) has provided an update on its financial position and NASDAQ listing status. The company reports a current cash position of $14 million, which is expected to fund operations into 2026. This runway will support their ongoing global Berubicin trial, with primary data analysis anticipated in the first half of 2025.

The company has implemented a reverse stock split to maintain NASDAQ compliance with minimum bid price requirements. Additionally, CNS Pharmaceuticals plans to initiate their TPI 287 clinical program with first patient consent targeted before year-end.

According to CEO John Climaco, the company is positioned for what they believe will be their most transformational year, with key milestones expected in the second half of 2025.

CNS Pharmaceuticals (NASDAQ:CNSP), a biopharmaceutical company focused on developing novel treatments for brain and central nervous system cancers, has announced its participation in the 18th Annual European Life Sciences CEO Forum in Zurich, Switzerland.

The company's CEO, John Climaco, will deliver a presentation on Wednesday, February 26, 2025, at 3:20 PM CET / 9:20 AM EST. Management will also be available for one-on-one meetings with qualified registered investors during the conference.

A video webcast of the presentation will be accessible on-demand through the conference presenters portal for registered attendees. The presentation represents an opportunity for CNS Pharmaceuticals to showcase its developments in primary and metastatic cancer treatments.

CNS Pharmaceuticals (NASDAQ:CNSP), a biopharmaceutical company focused on developing treatments for brain and central nervous system cancers, has participated in the Virtual Investor 'Top 5 for '25' On-Demand Conference. CEO John Climaco presented the company's top five investment highlights for 2025. The presentation is now available for viewing on the company's website and through the conference platform.

CNS Pharmaceuticals (NASDAQ:CNSP) has announced a 1-for-50 reverse stock split effective February 21, 2025. The company's stock will continue trading on Nasdaq under the same symbol 'CNSP' but with a new CUSIP number: 18978H409.

The reverse split is primarily aimed at increasing the per-share trading price and achieving compliance with Nasdaq's minimum share price requirements. For every 50 shares currently held, stockholders will receive one share. The company will make cash payments in lieu of fractional shares.

All outstanding warrants and equity-based awards will be proportionally adjusted by dividing underlying shares by 50 and multiplying exercise/conversion prices by 50. The par value remains at $0.001 per share, and the authorized share count stays at 300 million shares.